Biotech portfolio updates – Exelixis, Spark, buying more gene therapy stocks
Exelixis – Decreasing exposure on valuation Exelixis (EXEL) continues to look very strong after hitting a 15-year high on Friday, which is never a bad point in time to realize some gains. While I still...
View ArticleGene therapy’s 2017 scorecard – No alarms and no surprises (please)
Readers of this blog know I have high hopes for gene therapy, a field with a checkered history but disruptive potential that may finally be ready for primetime. After two years of dramatic progress...
View Article
More Pages to Explore .....